SUZUKEN CO.,LTD.
9987・Prime Market・Wholesale Trade
Pharmaceutical Wholesale Business
The core business of the Suzuken Group, responsible for the nationwide wholesale distribution of prescription drugs, diagnostic reagents, medical devices, and related products.
| Period | Current | Previous | Change |
|---|---|---|---|
| Net sales (full year, FY2026 (ending March 2026)) | ¥2,401,013 million | ¥2,313,967 million | ↑ |
| Operating income (full year, FY2026 (ending March 2026)) | ¥31,467 million | ¥31,916 million | ↓ |
| Segment assets (full year, FY2026 (ending March 2026)) | ¥1,038,140 million | ¥987,026 million | ↑ |
| Depreciation and amortization (full year, FY2026 (ending March 2026)) | ¥10,427 million | ¥10,233 million | ↑ |
| Increase in property, plant and equipment and intangible assets (full year, FY2026 (ending March 2026)) | ¥17,277 million | ¥18,811 million | ↓ |
Business Details
The segment's core companies are Suzuken Co., Ltd. itself, along with Sanki Co., Ltd., Asutisu Co., Ltd., Shoyaku Co., Ltd., Suzuken Okinawa Yakuhin Co., Ltd., Nakano Yakuhin Co., Ltd., Suzuken Iwate Co., Ltd., and S.D. Logi Co., Ltd. Serving medical institutions, pharmacies, and pharmaceutical manufacturers as customers, the segment sells prescription drugs, diagnostic reagents, medical devices, and medical materials. The segment is advancing distribution quality improvement and productivity gains through the rollout of the specialty pharmaceutical traceability system "Cubixx" and automation/labor-saving initiatives enabled by the operation of the Metropolitan Area Logistics Center.
Recent Overview
Net sales rose 3.8% year on year, but operating income declined 1.4% due to increased costs.
Net sales for FY2026 (ending March 2026) were ¥2,401,013 million (up 3.8% year on year). Although sales of COVID-19-related products declined from the previous year, revenue increased on the back of growth in the prescription drug market and contributions from new drugs such as specialty pharmaceuticals. On the other hand, operating income was ¥31,467 million (down 1.4% year on year). Amid rising costs, including responses to the Distribution Improvement Guidelines revised in April 2024 and increased logistics outsourcing fees, the company was unable to fully offset the rise in procurement costs for pharmaceuticals through reviews and control of SG&A expenses.
Key Products
Growth Drivers
- Growth in the prescription drug market (expansion of the antineoplastic agent market and contribution from new drugs such as specialty pharmaceuticals)
- Strengthening of the specialty pharmaceutical distribution infrastructure (nationwide rollout and functional expansion of the Cubixx system)
- Automation, labor savings, and reduced transportation costs from operation of the Metropolitan Area Logistics Center (Soka City, Saitama Prefecture)
- Strengthening of the logistics network through construction of the Chubu Area Logistics Center (tentative name, Kasugai City, Aichi Prefecture; construction scheduled to begin October 2027)
- Development of new revenue models through MS activities and improved productivity and customer satisfaction via digital tool utilization
- Strengthening profitability through response to the Distribution Improvement Guidelines revised in April 2024 and review/control of SG&A expenses
Risks
- Profit pressure from rising procurement costs for pharmaceuticals and increased operating expenses due to inflationary trends in outsourcing and other costs
- Reduced scope for revenue growth due to declining sales of COVID-19-related products (treatments, diagnostics, etc.)
- Downward pressure on selling prices from drug price revisions
- Rising logistics costs driven by progressing labor shortages, exemplified by the "2024 Problem"
- Increasingly sophisticated information security risks such as ransomware (impact on pharmaceutical distribution infrastructure)
- Risk of sales figure revisions due to prolonged undetermined pricing for certain pharmaceuticals (uncertainty in revenue recognition)
Last updated: June 22, 2026